REVB Revelation Biosciences, Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. REVTx-99, its lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for complete immunity. The company is also developing REVDx-501, a rapid point-of-care diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation.
$1.53 +0.16 (11.68%)
As of 03/24/2023 16:00:00 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: Common stocks
Category3: Micro cap
GICS sector: Health Care
Industry: Biotechnology
Index country: USA
Country of incorporation:
IPO date: 12/10/2013
Outstanding shares: 23,536,070
Average volume: 360,731
Market cap: $32,244,416
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Quarterly filings: 10-Q
Annual filings: 10-K
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%